<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
OCTOBER 1, 1997
TEXAS BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
NO. 1-12574
(Commission File Number)
13-3532643
(I.R.S. Employer Identification No.)
7000 FANNIN, SUITE 1920
HOUSTON, TEXAS 77030
(Address of Principal Executive Offices)
(713) 796-8822
(Registrant's Telephone Number, Including Area Code)
<PAGE> 2
ITEM 5. OTHER EVENTS
On October 1, 1997, Texas Biotechnology Corporation announced the completion of
a public offering of 5 million shares of common stock at a price of $5.00 per
share. The Company also sold on October 3, 1997, an additional 750,000 shares of
common stock to cover over-allotments. As of October 3, 1997, Texas
Biotechnology Corporation had 32,310,512 million shares outstanding. The
offering was underwritten by Lehman Brothers and PaineWebber Incorporated. The
net proceeds from the offering will be used to fund preclinical and clinical
testing of the Company's product candidates, continued research and development,
and capital expenditures.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Date: October 9, 1997 TEXAS BIOTECHNOLOGY CORPORATION
-------------------------------
(Registrant)
By: /S/ STEPHEN L. MUELLER
-------------------------------
Stephen L. Mueller
Vice President of Administration,
Secretary and Treasurer
